Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Finerenone for Heart Failure in People Having a Heart Valve Replacement

Tests finerenone against placebo in heart failure patients having transcatheter aortic valve implantation.

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Tianjin, Ürümqi, Wenzhou, Wuhan, Xi’an, and Zhengzhou, ChinaSee the 61 sites
Trial code
Registry title
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
Status
Recruiting
Phase
Phase 3
People taking part
2,832 people, planned
Started
9 Oct 2026
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Finerenone
  • Placebo
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 65 or older with severe aortic stenosis who are having a TAVI procedure through the groin artery and who also have heart failure. It tests finerenone against placebo.

Age
65 years or older
Sex
All sexes can join.
Disease stage
Severe aortic stenosis (aortic valve area < 1.0 cm2 or indexed area < 0.6 cm2/m2, or mean gradient ≥ 40 mmHg, or flow velocity ≥ 4.0 m/s) with transfemoral TAVI planned. Heart failure symptoms of NYHA class ≥ II and left ventricular ejection fraction ≥ 40% before TAVI.
Earlier treatment
Must be undergoing transfemoral TAVI. Cannot have a known allergy, intolerance or contraindication to mineralocorticoid receptor antagonists.
Biomarker or test result
Untreated potassium must not be above 5.0 mmol/L. Estimated glomerular filtration rate (kidney function) must not be below 25 ml/min/1.73 m².

Main reasons for not taking part

  • Untreated potassium above 5.0 mmol/L
  • Estimated glomerular filtration rate below 25 ml/min/1.73 m²
  • Heart attack, stroke or mini-stroke within 30 days before randomization, or such an event or a CRT device implant planned
  • Pregnant or breastfeeding
  • Life expectancy under 1 year

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 65 years
  • Patients with severe aortic stenosis (aortic valve area < 1.0 cm2 or indexed area < 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI
  • New York Heart Association class ≥ II
  • Left ventricular ejection fraction ≥ 40% at baseline prior TAVI
  • Informed consent has been signed

Who cannot take part

  • Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or transient ischemic attack within 30 days prior to randomization
  • Currently participating in a cardiovascular investigational drug or another device study and not yet completed follow-up for the primary endpoint
  • Known allergy, intolerance, or contraindication to mineralocorticoid receptor antagonists
  • Untreated serum/plasma potassium > 5.0 mmol/L during the screening period or randomization visit
  • Estimated glomerular filtration rate < 25 ml/min/1.73 m²
  • Pregnant or breastfeeding patients
  • Life expectancy < 1 year

Where in China

  • Affiliated Beijing Chaoyang Hospital of Capital Medical UniversityBeijing, ChinaContact: Li Xu, MDNot yet recruiting
  • Beijing Anzhen Hospital Affiliated to Capital Medical UniversityBeijing, ChinaContact: Guangyuan Song, MDNot yet recruiting
  • Chinese People's Liberation Army General HospitalBeijing, ChinaContact: Yundai Chen, MDNot yet recruiting
  • Fuwai Hospital Chinese Academy of Medical SciencesBeijing, ChinaContact: Yongjian Wu, MDNot yet recruiting
  • Peking University Third HospitalBeijing, ChinaContact: Yida Tang, MDNot yet recruiting
  • The First Affiliated Hospital of Bengbu Medical UniversityBengbu, ChinaContact: Jinjun Liu, MDNot yet recruiting
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Zhenfei Fang, MDNot yet recruiting
  • Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Yongping Bai, MDNot yet recruiting
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Biao Cheng, MDNot yet recruiting
  • West China Hospital，Sichuan UniversityChengdu, ChinaContact: Mao Chen, MDNot yet recruiting
  • Army Medical Center of the People's Liberation ArmyChongqing, ChinaContact: Gengze Wu, MDNot yet recruiting
  • The First Affiliated Hospital of Army Medical UniversityChongqing, ChinaContact: Zhihui Zhang, MDNot yet recruiting
  • the second affiliated hospital of Army medical universityChongqing, ChinaContact: Jun Jin, MDNot yet recruiting
  • Fujian Medical University Union HospitalFuzhou, ChinaContact: Liangwan Chen, MDNot yet recruiting
  • Fuzhou University Affiliated Provincial HospitalFuzhou, ChinaContact: Yansong Guo, MDNot yet recruiting
  • Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Jianfang Luo, MDNot yet recruiting
  • Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaContact: Jiancheng Xiu, MDNot yet recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Yangxin Chen, MDNot yet recruiting
  • The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Xiaodong Zhuang, MDNot yet recruiting
  • The First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Weidong Li, MDNot yet recruiting
  • The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Xianbao Liu, MDTaking people
  • The Sir Run Run Shaw Hospital of Zhejiang University School of MedicineHangzhou, ChinaContact: Guosheng Fu, MDNot yet recruiting
  • The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaContact: Chao Gao, MDNot yet recruiting
  • Qilu Hospital of Shandong UniversityJinan, ChinaContact: Guipeng An, MDNot yet recruiting
  • Shandong Provincial Qianfoshan HospitalJinan, ChinaContact: Xiaozhou Zheng, MDNot yet recruiting
  • The First Hospital of Lanzhou UniversityLanzhou, ChinaContact: Ming Bai, MDNot yet recruiting
  • Jiangsu Provincial People's HospitalNanjing, ChinaContact: Xiangqing Kong, MDNot yet recruiting
  • Nanjing Drum Tower hospitalNanjing, ChinaContact: Dongjin Wang, MDNot yet recruiting
  • Nanjing First HospitalNanjing, ChinaContact: Junjie Zhang, MDNot yet recruiting
  • Zhongda Hospital Southeast UniversityNanjing, ChinaContact: Genshan Ma, MDNot yet recruiting
  • Ningbo Medical Center Lihuili HospitalNingbo, ChinaContact: Zhikui Chen, MDNot yet recruiting
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaContact: Xiaomin Chen, MDNot yet recruiting
  • QingDao Municipal HospitalQingdao, ChinaContact: Yibing Shao, MDNot yet recruiting
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Lei Jiang, MDNot yet recruiting
  • Renji Hospital, Shanghai Jiaotong University School of MedicineShanghai, ChinaContact: Jun Pu, MDNot yet recruiting
  • Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaContact: Ruiyan Zhang, MDNot yet recruiting
  • Shanghai Chest HospitalShanghai, ChinaContact: Xin Pan, MDNot yet recruiting
  • Shanghai East HospitalShanghai, ChinaContact: Qi Zhang, MDNot yet recruiting
  • The First Affiliated Hospital of Naval Medical UniversityShanghai, ChinaContact: Yuan Bai, MDNot yet recruiting
  • Xinhua Hospital Affiliated To Shanghai Jiao tong University School of MedicineShanghai, ChinaContact: Li Zhang, MDNot yet recruiting
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Daxin Zhou, MDNot yet recruiting
  • Liaoning Provincial People's HospitalShenyang, ChinaContact: Bo Luan, MDNot yet recruiting
  • People's Liberation Army Northern Theater Command General HospitalShenyang, ChinaContact: Kai Xu, MDNot yet recruiting
  • The First Hospital of China Medical UniversityShenyang, ChinaContact: Liang Guo, MDNot yet recruiting
  • Tianjin Chest HospitalTianjin, ChinaContact: Nan Jiang, MDNot yet recruiting
  • Tianjin First Central HospitalTianjin, ChinaContact: Chengzhi Lu, MDNot yet recruiting
  • The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaContact: Yitong Ma, MDNot yet recruiting
  • Xinjiang Uygur Autonomous Region People's HospitalÜrümqi, ChinaContact: Yining Yang, MDNot yet recruiting
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Hao Zhou, MDNot yet recruiting
  • The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Lianping Wu, MDNot yet recruiting
  • Renmin Hospital of Wuhan UniversityWuhan, ChinaContact: Hong Jiang, MDNot yet recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Hesong Zeng, MDNot yet recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Xiaoke Shang, MDNot yet recruiting
  • Zhongnan Hospital of Wuhan UniversityWuhan, ChinaContact: Jinping Liu, MDNot yet recruiting
  • The First Affiliated Hospital of Air Force Medical UniversityXi’an, ChinaContact: Jian Yang, MDNot yet recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaContact: Zuyi Yuan, MDNot yet recruiting
  • The Second Affiliated Hospital of Air Force Medical UniversityXi’an, ChinaContact: Yan Li, MDNot yet recruiting
  • Fuwai Huazhong Cardiovascular HospitalZhengzhou, ChinaContact: Yiqiang Yuan, MDNot yet recruiting
  • Henan Chest HospitalZhengzhou, ChinaContact: Qiong Huang, MDNot yet recruiting
  • The First Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaContact: Chunguang Qiu, MDNot yet recruiting
  • Zhengzhou No.7 People's HospitalZhengzhou, ChinaContact: Shenwei Zhang, MDNot yet recruiting

About the trial

What the trial wants to find out

This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 months at clinic, and 3 months, 6 months, 9 months and every 6 months after 12 months of enrollment online or via telephone (at clinic if necessary). The final visit will be conducted for all enrolled patients at the end of the study.

The 2 groups in the trial

  • Treatment GroupTreatment being tested

    Oral treatment with finerenone daily: * For participants with an eGFR ≤60 mL/min/1.73 m2: Starting dose is 10 mg OD and target dose 20 mg OD. * For participants with an eGFR \>60 mL/min/1.73 m2: Starting dose is 20 mg OD and target dose 40 mg OD.

    Treatment: Finerenone

  • Control GroupPlacebo, for comparison

    Oral treatment with placebo daily

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure: A Prospective, Multicenter, Randomized, Placebo-Controlled Trial
Plain-language title
Finerenone for Heart Failure in People Having a Heart Valve ReplacementGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 October 2026